Secondary market transactions have propelled Neuralink’s implied valuation from its June 2025 Series E level near $9 billion to estimates between $42 billion and $59.8 billion as of mid-October 2026, driven by robust investor demand for its brain-computer interface technology. Private trades tracked by platforms such as Caplight and Nasdaq Private Market reflect this surge, fueled by clinical progress including 21 human implants, expanded trials for motor control and speech, and the Blindsight vision-restoration device receiving FDA breakthrough status. With resolution by October 31, near-term sentiment hinges on any additional secondary prints or announcements that could shift the latest marks, though the private-company structure limits transparency and introduces volatility around sparse data points.